MedTrace Logo

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

NCT00699296 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2012-11-27

No results posted yet for this study

Summary

This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma. LBH589 is administered orally once a day for three days per week.

Conditions

  • Cutaneous T-Cell Lymphoma
  • Leukemia-Lymphoma, Adult T-Cell

Interventions

DRUG

Panobinostat (LBH589)

20mg/day p.o. on three times-a- week

Sponsors & Collaborators

Principal Investigators

  • Makoto Sugaya · The University of Tokyo Hospital

  • Kenji Iwatsuki · Okayama University

  • Yoshiki Tokura · University Hospital of Occupational and Environmental Health

  • Kunihiro Tsukasaki · Nagasaki University Hospital of Medicine and Dentistry

  • Hironobu In · Kumamoto University Hospital

  • Mitsuru Setoyama · University of Miyazaki Hospital

  • Atae Utsunomiya · Imamura Bun-in Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699296 on ClinicalTrials.gov